Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

Running, not enrolling · Phase 2

Conditions studied: Multiple Myeloma

In brief

A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.

Key facts

Study ID: NCT05396885
Run by: Kite, A Gilead Company
People needed: 136
Starts: 2022-07-15
Expected to finish: 2026-12-01
Last updated by the study team: 2026-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age 18 years or older and has capacity to give informed consent
Relapsed or refractory multiple myeloma treated with at least 3 prior regimens of systemic therapy including proteasome inhibitor, immunomodulatory drugs (IMiD) and anti-CD38 antibody and are refractory to the last line of therapy. For each line, 2 consecutive cycles are required unless the best response after 1 cycle was progressive disease.
Note: IMWG criteria defines refractory disease as non-responsive to therapy or disease progression on or within 60 days of a therapy Note: Induction treatment with or without hematopoietic stem cell transplant and with or without maintenance is considered a single regimen
Documented measurable disease including at least one or more of the following criteria:
Serum M-protein ≥1.0 g/dL
Urine M-protein ≥200 mg/24 hours
Involved serum free light chain ≥10 mg/dL with abnormal κ/λ ratio (i.e., >4:1 or <1:2)
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Life expectancy >12 weeks
Adequate organ function defined as:
Oxygen (O2) saturation ≥92% on room air
Left Ventricular Ejection Fraction (LVEF) ≥45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
Absolute neutrophil count (ANC) ≥1.0k/µl, platelet count (PLT)
≥50k/µl, [NOTE: Platelet transfusion not allowed within 14 days; filgrastim (or biosimilar) not allowed within 7 days, pegfilgrastim (or biosimilar) within 14 days]
Creatinine clearance ≥45 mL/min min (as determined by the Cockgroft-Gault equation) and not on dialysis
Aspartate transaminase (AST)/alanine transaminase (ALT) <3 x upper limits of normal (ULN)
Total bilirubin <1.5 x ULN (allow 3x ULN for Gilbert's syndrome)
Prothrombin time test (PTT), prothrombin time (PT)/international normalized ratio (INR) <1.5 x ULN, unless on a stable dose of anti-coagulant for a thromboembolic event (Subjects with any history of thromboembolic stroke; or history or Grade 2 (G2) or greater hemorrhage within one year are excluded)
Resolution of adverse events (AEs) from any prior systemic anticancer therapy, radiotherapy, or surgery to Grade 1 or baseline (except G2 alopecia and G2 sensory neuropathy)
Male and female participants of childbearing potential must agree to use highly effective methods of birth control through 12 months after the dose of study treatment
Willing to comply with and able to tolerate study procedures, including consent to participate in separate Long-term Safety Follow-up lasting up to 15 years per FDA guidance
Subject's leukapheresis product from non-mobilized cells is received and accepted for cell processing by manufacturing site. NOTE: Leukapheresis will be performed only after all other eligibility criteria are confirmed

You may not qualify if…

Plasma cell leukemia or history of plasma cell leukemia
Treatment with the following therapies as specified below
Any prior systemic treatment for multiple myeloma within the 14 days prior to scheduled leukapheresis
Receiving high-dose (e.g., >10 mg prednisone or equivalent) systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to leukapheresis
Prior treatment with any gene therapy, gene-modified cellular immune-therapy, or T cell engager
Prior B-cell maturation antigen (BCMA) directed therapy
Autologous stem cell transplantation within 3 months prior to leukapheresis, or any prior allogeneic stem cell transplantation
Subjects with solitary plasmacytomas without evidence of other measurable disease are excluded
History of allergy or hypersensitivity to study drug components. Subjects with a history of severe hypersensitivity reaction to dimethyl sulphoxide (DMSO) are excluded
Contraindication to fludarabine or cyclophosphamide
Severe or uncontrolled intercurrent illness or laboratory abnormalities including
Active bacterial, viral, or fungal infection requiring systemic treatment (isolated fever may not constitute active infection in and of itself, (e.g., related to disease)
Symptomatic congestive heart failure (i.e., New York Heart Association stage III or IV)
Unstable angina, arrhythmia, or myocardial infarction (MI) within 6 months prior to Screening
Significant pulmonary dysfunction
Uncontrolled thromboembolic events or recent severe hemorrhage (i.e., within one year)
Any history of pulmonary embolism (PE) in the past 12 months or deep vein thrombosis (DVT) within three months of enrollment. Therapeutic dosing of anticoagulants (e.g., warfarin, low molecular weight heparin, Factor Xa inhibitors) is allowed for history of PE/DVT if greater than twelve and three months, respectively, from time of enrollment, and should be at a stable maintenance dose.
Auto-immune disease requiring immunosuppressive therapy within the last 24 months
Seropositive for and with evidence of active hepatitis B or C infection at time of Screening, or HIV seropositive
Subjects with a history of hepatitis B but have received antiviral therapy and have non-detectable viral DNA are eligible
Subjects seropositive because of hepatitis B virus vaccine with no signs or active infection are eligible
Subjects who had hepatitis C but have received antiviral therapy and show no detectable hepatitis C virus (HCV) viral RNA are eligible
Active central nervous system (CNS) involvement by malignancy
Any sign of active or prior CNS pathology including but not limited to history of epilepsy, seizure, paresis, aphasia, stroke, subarachnoid hemorrhage or CNS bleed, severe brain injury, dementia, cerebellar disease, Parkinson's disease, organic brain syndrome or psychosis
Active malignancy not related to myeloma that has required therapy in the last 3 years or is not in complete remission. Exceptions to this criterion include successfully treated non-metastatic basal cell or squamous cell skin carcinoma, or prostate cancer that does not require therapy.

Where it is running

HonorHealth Cancer Transplant Institute — Scottsdale, Arizona, United States
University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
Colorado Blood Cancer Institute — Denver, Colorado, United States
Moffitt Cancer Center — Tampa, Florida, United States
Northside Hospital — Atlanta, Georgia, United States
University of Chicago Medical Center — Chicago, Illinois, United States
University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland, United States
Massachusetts General Hospital — Boston, Massachusetts, United States
Dana-Farber Cancer Institute — Boston, Massachusetts, United States
Karmanos Cancer Institute — Detroit, Michigan, United States
John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States
Levine Cancer Institute — Charlotte, North Carolina, United States
Oregon Health & Science University (OHSU) — Portland, Oregon, United States
University of Texas Southwestern Medical Center — Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah, United States
University of Wisconsin Clinical Science Center — Madison, Wisconsin, United States
Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.